

3 April 2025

BIOXYNE SIGNS EXCLUSIVE \$7M MANUFACTURING AND SUPPLY AGREEMENT WITH EXISTING CLIENT

Highlights

- BLS appointed as the exclusive manufacturer of all NectarTek products for distribution in Australia, the UK, and Germany.
- Agreement includes volume commitments expected to generate at least \$7 million in revenue for BXN in FY2026, with orders ramping up immediately.
- NectarTek is a well-established Australian healthcare company operating multi-state, international clinics and distributing alternative medicines.
- The commitment represents a 200% increase over expected FY2025 revenues from NectarTek.

Bioxyne Limited (ASX:BXN) ("**Bioxyne**" or the "**Company**"), an Australian pharmaceutical and consumer health products company and parent company of Breathe Life Sciences ("**BLS**"), is pleased to announce a formalized manufacturing and supply agreement with its existing customer, NectarTek Australia Pty Ltd (the "**Customer**").

Under the agreement, based on committed volumes, BLS expects to generate at least \$7 million in sales from NectarTek in FY2026.

The contract includes minimum order volumes of:

- \$3.6 million of pastilles
- \$2.5 million of packed flower products
- \$0.5 million of vapes
- \$0.5 million of oral mucosal oils and other products

NectarTek has committed to ordering these quantities from **1 July 2025 to 30 June 2026**. The agreement may be terminated with six months' written notice. The contract's minimum order value of approximately **\$7 million** represents a **200% increase** over historical orders from NectarTek. Actual order volumes for FY2026 may exceed these minimum commitments.

Bioxyne continues to strengthen its position as the leading manufacturer and supplier of alternative pharmaceuticals, including cannabis products for authorized prescribers and clinical trials in domestic and international markets. The Company anticipates securing additional long-term contracts following a substantial increase in manufacturing capacity across all product categories with the potential to generate revenue of over **\$100 million per year**.



Jarrad Hand, CEO of NectarTek commented, *“our mission is to help patients and doctors treat the many conditions where other treatments have failed, reduce the suffering and educate the health community about alternative therapies. We have been working with BLS for over 12 months, during which time our business has grown substantially and is underpinned by our strong relationship. This new manufacturing and supply agreement, which gives BLS exclusivity and NectarTek improved credit terms will help us to continue our growth trajectory.”*

Sam Watson, Bioxyne CEO commented, *"This agreement with NectarTek underscores market trust in BLS and our ability to deliver value to industry partners, clients, and stakeholders. Exclusivity is a privilege we have earned by consistently delivering results and supporting our clients' growth. BLS is Australia's leading manufacturer of alternative pharmaceuticals and continues to strengthen its position. We are excited about this collaboration's future, particularly as we expand into the UK and Germany in the coming months."*

About NectarTek:


NectarTek is an established Australian healthcare company and wholesale pharmaceutical distributor. The company operates clinics providing patient services and prescription medicinal products across Australia, the UK, and Germany.

This announcement has been approved for release by the Board.

For further information contact:

Sam Watson
Managing Director
Bioxyne Limited
sam@breathelifesciences.com

Guy Robertson
Chief Financial Officer
Bioxyne Limited
guy@bioxyne.com



Bioxyne Activity Worldwide



About Bioxyne Ltd.

Bioxyne Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, sponsor, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA..

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. Our corporate head office is in Sydney, and our operations extend to licensed manufacturing, warehousing, import/export, sales and distribution centers in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

Our business model is focused on manufacturing final dose form finished products, sales and distribution in each of the territories we serve. We work with raw materials and API suppliers in 5 continents and are a market leader in the manufacture of novel / investigational therapeutic goods. .

The BLS logo is derived from a Japanese Maple Leaf, symbolising health, happiness and a long life well lived. While the Japanese Maple is not a medicinal plant, our company purpose is to redefine medicine by taking a holistic approach to healthcare for a healthier and happier tomorrow. Outside of Australia the BLS Group operates a health and wellness products and brands business focussed on naturally derived active nutraceuticals, wellness and lifestyle supplements and cannabidiol (CBD) based novel foods. It primarily operates in the UK, Europe and Japan, and engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand – Dr Watson is an internationally recognized health, lifestyle, and prescription products brand. Dr Watson products consist of cannabis-based food supplements, lifestyle products, cosmetics, functional mushrooms and nootropics, and prescription medicines in Australia;
- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe;
- c) White label manufacture of third-party wellness and supplements brands in Japan, UK and Europe in company-owned facilities;
- d) Research and development; and
- e) Direct sales via online and wholesale sales of BLS-owned consumer brands, such as Dr Watson®
 - **United Kingdom:** drwatsoncbd.com



- **Japan:** nolcbn.com
- f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

Corporate: <https://bioxyne.com>

Australia: <https://bls.com.au>;

International: <https://breathelifesciences.com>

